Company intelligence / Profile preview
TC BioPharm
Glasgow, Scotland, United Kingdomtcbiopharm.com ↗
- Ownership
- Public · TCBP
- Employees
- ~100
- Development stage
- Other
01
Overview
TC BioPharm has demonstrated human efficacy data in acute myeloid leukemia and leads the field as the first company to conduct phase II/pivotal clinical studies with gamma-delta T cells in oncology. The company’s lead program uses its proprietary CryoTC technology to deliver frozen allogeneic products globally. Two investigator-led trials are ongoing for unmodified gamma-delta T cell products.
- Therapeutic areas
- OncologyInfectious DiseasesHematology
- Modalities
- Allogeneic CAR-T cell therapyGamma delta T cell therapy
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
bluebird bio (CAR-engineered gamma delta program)NIPRO Corporation (co-developing novel CAR-T product)Scotia Biologics (cancer-targeting single-chain antibodies)
Beyond the preview
Go deeper on TC BioPharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TC BioPharm.